Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets
Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results
Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call Transcript
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
Accelerate Diagnostics Reports Third Quarter 2024 Financial Results
Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results
Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System
Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial
Accelerate Diagnostics, Inc. (AXDX) Q2 2024 Earnings Call Transcript
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
Accelerate Diagnostics Reports Second Quarter 2024 Financial Results
Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial
Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results
Dead Cat Bounce: 3 Stocks to Sell Before They Plunge Again
Accelerate Diagnostics, Inc. (AXDX) Q1 2024 Earnings Call Transcript
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results
Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know
Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results.
Accelerate Diagnostics Inc. (AXDX) Q4 2023 Earnings Call Transcript
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.
Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement
Accelerate Diagnostics Announces Launch of Proposed Public Offering
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results
Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®
Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Accelerate Diagnostics, Inc. (AXDX) Q3 2023 Earnings Call Transcript
Accelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results.
Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?
Accelerate Diagnostics, Inc. (AXDX) Q2 2023 Earnings Call Transcript
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
Accelerate Diagnostics Reports Second Quarter 2023 Financial Results
Accelerate Diagnostics Scheduled Call to Review 2023 Second Quarter Results
Accelerate Diagnostics Announces 1-for-10 Reverse Stock Split
Is Accelerate Diagnostics (AXDX) Stock Outpacing Its Medical Peers This Year?
Accelerate Diagnostics Announces Successful Completion of Debt Restructuring Support Agreement, Supporting Advancement of Next-Generation Platform Wave
Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?
Accelerate Diagnostics, Inc. (AXDX) Q1 2023 Earnings Call Transcript
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
Accelerate Diagnostics Reports First Quarter 2023 Financial Results
Accelerate Diagnostics scheduled call to review 2023 first quarter results
Forget Bargain Hunting, Buy 5 Stocks With Rising P/E
Accelerate Diagnostics (AXDX) Upgraded to Buy: What Does It Mean for the Stock?
Accelerate Diagnostics, Inc. (AXDX) Q4 2022 Earnings Call Transcript